HA-1 TCR T Cells

Developed for: acute biphenotypic leukemia · acute undifferentiated leukemia · adult acute lymphoblastic leukemia · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · CD4+/CD56+ hematodermic neoplasm · childhood acute lymphoblastic leukemia · childhood acute myeloid leukemia · juvenile myelomonocytic leukemia
+1 more
· myelodysplastic syndrome
Investigated by: Fred Hutchinson Cancer Center · HighPass Bio, Inc. · PromiCell Therapeutics, Inc.

today NCT03326921 · Ph 1

20182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03326921	Feb 2018 → Oct 2027 expected	CD4+/CD56+ hematodermic neoplasm, acute biphenotypic leukemia, acute undifferentiated leukemia, adult acute lymphoblastic leukemia +5	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	HA-1 TCR T Cells	“HA-1 TCR T Cells” NCT03326921 ↗
Modality	Cell therapy	“CD8+ and CD4+ T cells expressing the HA-1 TCR and a CD8 coreceptor were successfully manufactured from HA-1-disparate HCT donors.” PMID 38683966 ↗ Sep 2024
Route	Intravenous	“Patients then receive CD4+ and CD8+ HA-1 TCR T cells intravenously (IV).” NCT03326921 ↗